Want to see CORT full AI Analyst Report?
Corcept Therapeutics (CORT) Stock Statistics & Valuation Metrics
Total Valuation
Corcept Therapeutics has a market cap or net worth of $8.77B. The enterprise value is $9.99B.
- Market Cap
- $8.77B
- Enterprise Value
- $9.99B
Share Statistics
Corcept Therapeutics has 108,098,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 108,098,400
- Owned by Insiders
- 10.65%
- Owned by Institutions
- 36.12%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.67%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.12
- Return on Invested Capital (ROIC)
- 6.67%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 1.04M
- Profits Per Employee
- 136.51K
- Employee Count
- 730
- Asset Turnover
- 0.91
- Inventory Turnover
- 1.01
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 156.00. Corcept Therapeutics’s PEG ratio is -2.66.
- PE Ratio
- 156.00
- PS Ratio
- 10.55
- PB Ratio
- 12.11
- Price to FCF
- 82.01
- Price to Operating Cash Flow
- 77.92
- PEG Ratio
- -2.66
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 761.41M and earned 99.65M in profits. Earnings per share was 0.95.
- Revenue
- 761.41M
- Gross Profit
- 748.43M
- Operating Income
- 44.80M
- Pretax Income
- 66.46M
- Net Income
- 99.65M
- EBITDA
- 68.35M
- Earnings Per Share (EPS)
- 0.95
Cash Flow
In the last 12 months, operating cash flow was 109.70M and capital expenditures -2.78M, giving a free cash flow of 106.92M billion.
- Operating Cash Flow
- 109.70M
- Free Cash Flow
- 106.92M
- Free Cash Flow per Share
- 1.01
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.23%
- Earnings Yield
- 0.65%
Stock Price Statistics
- Beta
- 0.52
- 52-Week Price Change
- 12.26%
- 50-Day Moving Average
- 111.76
- 200-Day Moving Average
- 75.48
- Relative Strength Index (RSI)
- 23.15
- Average Volume (3m)
- 1.17M
Important Dates
Corcept Therapeutics upcoming earnings date is Nov 03, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Nov 03, 2026
- Ex-Dividend Date
- ―
Financial Position
Corcept Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 0.94%
- Current Ratio
- 2.92
- Quick Ratio
- 2.85
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.67
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid -33.19M in taxes.
- Income Tax
- -33.19M
- Effective Tax Rate
- -0.50
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 298.55, with an EV/FCF ratio of 80.39.
- EV to Sales
- 10.35
- EV to EBITDA
- 298.55
- EV to Free Cash Flow
- 80.39
- EV to Operating Cash Flow
- 78.35
Balance Sheet
Corcept Therapeutics has $308.20M in cash and marketable securities with $9.42M in debt, giving a net cash position of $298.78M billion.
- Cash & Marketable Securities
- $308.20M
- Total Debt
- $9.42M
- Net Cash
- $298.78M
- Net Cash Per Share
- $2.76
- Tangible Book Value Per Share
- $6.70
Margins
Gross margin is 98.30%, with operating margin of 0.77%, and net profit margin of 6.61%.
- Gross Margin
- 98.30%
- Operating Margin
- 0.77%
- Pretax Margin
- 3.17%
- Net Profit Margin
- 6.61%
- EBITDA Margin
- 3.47%
- EBIT Margin
- 3.17%
Analyst Forecast
The average price target for Corcept Therapeutics is $163.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $163.75
- Price Target Upside
- 101.86% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 16.02%
- EPS Growth Forecast
- -59.24%
Scores
- Smart Score
- 8
- AI Score
- 69
